Development And Commercialization Agreement With Nxera
Yesterday 06:02
BRIEF-Idorsia Initiates Pivotal Phase 3 Study For Lucerastat In Fabry Disease And Enters Co-Development And Commercialization Agreement With Nxera Oct 28 (Reuters) - IDORSIA LTD IDIA.S:
IDORSIA INITIATES PIVOTAL PHASE 3 STUDY FOR LUCERASTAT IN FABRY DISEASE AND ENTERS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH NXERA
NXERA TO HOLD COMMERCIALIZATION RIGHTS FOR LUCERASTAT IN JAPAN AND SELECTED ASIA PACIFIC MARKETS
NXERA TO PAY IDORSIA CHF 7 MILLION AND CONTRIBUTE TO PHASE 3 DEVELOPMENT
Source text: ID:nGNE7F5gBW
Further company coverage: IDIA.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))